Senior Director HEOR

The Lotus Group LLC; United States; On-site; USD 180,000 - 260,000; Full time

Job summary

The Lotus Group LLC is seeking a Senior Director, HEOR to lead health economics, outcomes research, and value evidence strategy for a leading oncology asset from late-stage development through launch and lifecycle management.

This hands-on leadership role drives the integrated evidence plan, engages payers and HTA bodies, and ensures evidence supports access and pricing at launch across markets including the US, EU, and priority ex-US regions.

Qualifications

• Advanced degree cover HEOR disciplines and leadership required.
• 12+ years in HEOR with at least 5 years in a leadership role.
• Oncology HEOR experience including survival endpoints and sequencing.
• Launch ownership of HEOR workstream for at least one product.
• Global value dossiers and HTA submissions in multiple agencies.
• Direct US payer experience and FDAMA Section 114 knowledge.
• Experience with real world evidence and patient reported outcomes programs.
• Ability to influence development decisions and protocol design.
• Vendor and budget management at asset level.

Responsibilities

• Own global value and evidence strategy across indications and lifecycle.
• Develop and maintain integrated evidence plan aligned to launch, pricing, and market access.
• Identify evidence gaps and design studies to close access risks.
• Translate trial design decisions into payer and HTA implications.
• Lead economic modeling including cost effectiveness and budget impact.
• Direct patient reported outcomes strategy and instrument validation.
• Lead real world evidence studies and network meta-analyses for HTA submissions.
• Ensure evidence meets HTA methodological standards in priority markets.
• Build global value dossier and adapt for country submissions.
• Engage payers and HTA bodies to test and refine value messaging ahead of submission.
• Support payer engagement and formulary positioning in the US.

Skills

HEOR leadership

Oncology HEOR

HTA submissions

Payer engagement

Real world evidence

Patient reported outcomes

Vendor management

Budget management

Survival endpoints

Launch experience

Education

Advanced degree in health economics, outcomes research, epidemiology, biostatistics, pharmacy, public health

PhD, PharmD, or MD preferred

Job description

The Senior Director, HEOR is the single point of accountability for the health economics, outcomes research, and value evidence strategy for a lead oncology asset moving from late stage development through launch and into lifecycle management. This is a program level role. The Senior Director owns the integrated evidence plan for the asset, sets priorities across markets, and represents HEOR on the asset leadership team.

This is a hands on leadership role. The Senior Director builds and directs the work, engages payers and HTA bodies directly, and is accountable for the evidence that supports access and pricing at launch.

Key Responsibilities

• Own the global value and evidence strategy for the asset across indications and lifecycle
• Develop and maintain the integrated evidence generation plan, aligned to launch sequence, pricing strategy, and market access requirements in the US, EU, and priority ex US markets
• Identify evidence gaps early and design studies to close them before they become access risks
• Translate clinical trial design decisions into downstream payer and HTA implications, and influence protocol design accordingly

Evidence Generation

• Lead the design and execution of economic models, including cost effectiveness, budget impact, and health state utility work
• Direct patient reported outcomes strategy, including instrument selection, validation, and endpoint positioning with regulators and payers
• Lead real world evidence studies, including natural history, treatment pattern, burden of illness, and comparative effectiveness work
• Direct systematic literature reviews and network meta analyses to support HTA submissions
• Ensure all evidence meets HTA methodological standards in priority markets

Launch and Access

• Build the global value dossier and adapt it for country submissions
• Partner with market access, pricing, and medical affairs to shape the payer value proposition and objection handling
• Engage payers, HTA bodies, and external experts to test and refine the value story ahead of submission
• Support US payer engagement, including formulary and pathway positioning
• Prepare HTA submissions and respond to assessor questions through the review process

Cross Functional Leadership

• Represent HEOR on the asset leadership team and in governance forums
• Partner with clinical development, biostatistics, medical affairs, regulatory, commercial, and market access
• Manage vendor selection, contracting, and performance for outsourced work
• Present evidence strategy and findings to senior leadership
• Publish and present outcomes research at congresses and in peer reviewed journals

Required Qualifications

• Advanced degree in health economics, outcomes research, epidemiology, biostatistics, pharmacy, public health, or a related field. PhD, PharmD, or MD preferred.
• 12 or more years in HEOR within pharma, biotech, or consulting, with at least 5 years in a leadership role
• Oncology experience is required. Candidates must have led HEOR strategy for an oncology asset, including work on survival endpoints, partitioned survival modeling, and treatment sequencing.
• Launch experience is required. Candidates must have owned the HEOR workstream for at least one product launch, from evidence planning through HTA submission and payer engagement.
• Demonstrated experience building global value dossiers and supporting HTA submissions in at least two of the following: NICE, G BA, HAS, CADTH, PBAC
• Direct experience with US payers, including value communication under FDAMA Section 114
• Track record of designing and executing real world evidence studies and patient reported outcomes programs
• Ability to influence clinical development decisions and protocol design
• Experience managing vendors and budgets at the asset level